Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting
24 Février 2017 - 1:00PM
Business Wire
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies for ocular diseases,
today announced three poster presentations at the American Glaucoma
Society 2017 Annual Meeting to be held March 2-5 in Coronado, CA.
The presentation details are as follows:
- Incidence of Hyperemia in the
Trabodenoson Monotherapy Clinical Development Program Through Phase
2Poster #: 87Authors: C Rich, LJ Katz, C Murray, N Dgetluck,
and R BaumgartnerDate: Friday, March 3, 2017Time: 7:00am to 8:00am
PST
- Improved Function of Retinal
Ganglion Cells by Topically Administered Trabodenoson in a Rat
Model of Optic Nerve Crush InjuryPoster #: 96Authors: A
Brockman, D Albers, J Tsai, C Rich, R Baumgartner, and W
McVicarDate: Friday, March 3, 2017Time: 7:00am to 8:00am PST
- Further Elucidation of the Mechanism
of Action of Trabodenoson Using Validated 3D-Human Trabecular
Meshwork ConstructsPoster #: 140Authors: D Albers, R Noecker, A
Unser, F Ahmed, K Torrejon, R Baumgartner, and W McVicarDate:
Saturday, March 4, 2017Time: 7:00am to 8:00am PST
Inotek will have an exhibition booth set up at #T27.
About Inotek Pharmaceuticals CorporationInotek
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
therapies for glaucoma and other eye diseases. The Company’s lead
product candidate, trabodenoson, is a first-in-class selective
adenosine mimetic currently in Phase 3 development. Trabodenoson
was developed in Inotek’s laboratories and is designed to restore
the eye’s natural pressure control mechanism. Additionally, the
Company is evaluating the potential for selective adenosine
mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit
www.inotekpharma.com. The inclusion of our website address here and
elsewhere in this press release does not include or incorporate by
reference the information on our website into this press
release.
Forward-Looking StatementsThis press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on
these statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may"
or similar expressions. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes.
Accordingly, you should not place undue reliance on these
forward-looking statements. All such statements speak only as of
the date made, and the Company undertakes no obligation to update
or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170224005032/en/
Inotek Contact:Claudine Prowse, PhD, 781-552-4305Vice
President, Corporate Development and IROIR@inotekpharma.com
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
INOTEK PHARMACEUTICALS CORP (NASDAQ:ITEK)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Inotek Pharmaceuticals Corp. (delisted) (NASDAQ): 0 recent articles
Plus d'articles sur Inotek Pharmaceuticals Corp. (MM)